COVID-19 is the acute pandemic, while antimicrobial resistance (AMR) is a silent, pandemic. New data makes the AMR pandemic visible, with the first global study of AMR estimating that 1.27 million people die from AMR every year, making AMR the 12th-leading cause of death globally.
G7 heads call for decarbonisation of industry
Latest NewsG7 Climate, Energy and Environment Ministers have announced a wide range of actions to tackle the triple global crisis of climate change, biodiversity loss and pollution".
Anti-ID antibody production
ProductsAn anti-idiotypic antibody (anti-ID Ab) can recognise and bind to the idiotypic center of another antibody. Anti-idiotype antibodies are widely used in therapeutic drug development, such as immunogenicity assessments, pharmacokinetic/pharmacodynamics (PK/PD) studies, and vaccine development.
Ellipses Pharma licences SRB22 from SunRock Biopharma
Latest NewsEllipses Pharma and SunRock Biopharma enter into a licensing agreement for a first-in-class bifunctional HER3:TRAIL fusion protein set to eliminate solid tumours.
The silent pandemic is not silent anymore
OpinionCOVID-19 is the acute pandemic, while antimicrobial resistance (AMR) is a silent, pandemic. New data makes the AMR pandemic visible, with the first global study of AMR estimating that 1.27 million people die from AMR every year, making AMR the 12th-leading cause of death globally.
Evotec signs contracts with Almirall and Sernova
Latest NewsHamburg-based CRO Evotec SE has inked a drug development partnership with Spanish Almirall SA in dematology.
Avantium gets EU grant
Latest NewsAvantium NV will get a €3m EU funding for a feasibility study of the electrochemical conversion of CO2 to consumer products.
Enzymaster raises $45m in Series C round
Latest NewsBiocatalysis expert Enzymaster (Germany, China, Singapore) has cashed in $45m to expand its production capacity of engineered biosynthetic enzymes.
EU starts consultation on novel plant breeding methods
Latest NewsThe EU Commission has launched its final consultation on the deregulation of new breeding techniques in agriculture.
Evotec and BMS intensify R&D on protein degraders
Latest NewsHamburg-headquartered Evotec SE has extended and expanded its three-year-old partnership with Bristol Myers Squibb in targeted protein degradation ("molecular glue degraders") for an additional eight years.
Bristol Myers Squibb brings in a huge library of E3 ligase modulators. Under the terms of the agreement, both parties will leverage all of Evotec’s appropriate platforms as well as AI/ML-based drug discovery.
Under the new agreement, Evotec cashes in an upfront payment of $200m and is eglible to obtain up to $5bn in milestone payments and tiered royalties on product sales.
New Laser Fluorescence Technique can deliver unique information in drug discovery
Sponsored PublicationsThe optically pumped semiconductor laser (OPSL) is an ideal light source for structured illumination microscopy (SIM), a laser fluorescence technique that can deliver unique information in drug discovery.